Results 81 to 90 of about 109,330 (215)

Hyaluronan in the pathogenesis of lupus nephritis in NZB/W mice and the effect of 4-methylumbelliferone

open access: yes, 2010
OBJECTIVES: Renal inflammation is a hallmark of lupus nephritis. Hyaluronan (HA) is a non-sulfated glycosaminoglycan ubiquitous in the extracellular environment of all cells.
Yung, S, Tse, WW, Chan, DTM, Ng, YCC
core   +1 more source

IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay   +3 more
wiley   +1 more source

Rapidly Progressive Glomerulonephritis Secondary to IgA Nephropathy in a Patient with Systemic Lupus Erythematosus

open access: yesCase Reports in Nephrology, 2019
Lupus nephritis is a common manifestation of systemic lupus erythematosus (SLE). IgA nephropathy is a common type of primary glomerulonephritis. Renal manifestations in SLE patients are often due to lupus nephritis; however, renal diseases unrelated to ...
Amol M. Patel   +5 more
doaj   +1 more source

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long   +3 more
wiley   +1 more source

Understanding lupus nephritis: diagnosis, management, and treatment options

open access: yes, 2012
Chi Chiu MokDepartment of Medicine, Tuen Mun Hospital and Center for Assessment and Treatment of Rheumatic Diseases, Pok Oi Hospital, Hong Kong, ChinaAbstract: Systemic lupus erythematosus (SLE) predominantly affects women in their reproductive years ...
Mok CC
core  

Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis.

open access: yes, 2015
A high level of galectin-3-binding protein (G3BP) appears to distinguish circulating cell-derived microparticles in systemic lupus erythematosus (SLE).
Rekvig, O P   +8 more
core   +1 more source

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio   +15 more
wiley   +1 more source

Expression and clinical significance of NGAL/NGALR in lupus nephritis

open access: yesLinchuang shenzangbing zazhi, 2017
Objective To investigate the expression and clinical significance of NGAL/NGALR in lupus nephritis( LN). Methods Eighty-four patients with systemic lupus erythematosus( SLE) were selected in this study,and divided into LN group and non-LN group.
ZENG Xing-ruo   +4 more
doaj  

CASTOR1 regulates humoral immune responses and contributes to the pathogenesis of systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives CASTOR1 senses arginine and regulates mammalian target of rapamycin complex 1 (mTORC1), a central metabolic signaling molecule. This study aimed to elucidate the roles of CASTOR1 in humoral immune responses. Methods We analyzed human B cell transcriptomes from healthy controls and patients with systemic lupus erythematosus (SLE) via ...
Takeshi Kusuda   +5 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy